Cytarabine-induced neurotoxicity responding to methyl prednisolone.
Malhotra
Pankaj
P
Mahi
Sushil
S
Lal
Vivek
V
Kumari
Savita
S
Jain
Sanjay
S
Varma
Subhash
S
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000209:etiology
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D008775:Methylprednisolone